IDEXX Laboratories Inc.

1 day ago · seekingalpha.com

IDEXX Laboratories continues to demonstrate robust growth, with Q3/26 results prompting an upward revision of FY26 revenue guidance to 10.1%-10.8%. VetLab consumables and CAG department revenues grew 16.1% and 11.3% respectively in the first nine months, underscoring core business strength. IDXX maintains pricing power, consistently passing on price increases and offsetting inflation, as evidenced by improved gross and operating margins.

1 day ago · seekingalpha.com

IDEXX Laboratories delivered strong Q3 results, beating expectations with 9.86% organic revenue growth and raising full-year revenue and EPS guidance. I maintain my buy rating on IDXX, citing its best-in-class diagnostics, high recurring revenue, and robust innovation pipeline supporting premium valuation. CoVet acquisition adds high-margin, AI-driven workflow software, enhancing stickiness and cross-selling, with a calculated purchase price near $223 million and double-digit growth potential.

2 days ago · zacks.com

From a technical perspective, Idexx Laboratories (IDXX) is looking like an interesting pick, as it just reached a key level of support. IDXX recently overtook the 200-day moving average, and this suggests a long-term bullish trend.

3 days ago · 247wallst.com

Retirement savers who never chose IDEXX Laboratories (NASDAQ:IDXX | IDXX Price Prediction) got a lift from it anyway on Monday. The veterinary diagnostics company was up 20.2% in the regular session as of 1:54 PM ET, trading at $662.

3 days ago · seekingalpha.com

IDEXX Laboratories, Inc. (IDXX) Q3 2026 Earnings Call Transcript

3 days ago · reuters.com

IDEXX raises forecast, betting diagnostics can offset weak vet visits

3 days ago · fool.com

IDEXX grew third-quarter revenue 10% to about $1.21 billion, led by an 11% gain in recurring diagnostics sales to vets. The higher 2026 profit forecast doesn't come from testing demand.

3 days ago · marketbeat.com

IDEXX Laboratories NASDAQ: IDXX reported third-quarter 2026 results marked by organic revenue growth, higher diagnostic utilization and expanded placement of its premium instruments, while raising its full-year revenue and earnings outlook.

3 days ago · zacks.com

While the top- and bottom-line numbers for Idexx (IDXX) give a sense of how the business performed in the quarter ended September 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

3 days ago · zacks.com

IDEXX Laboratories beats Q3 2026 earnings and revenue estimates as diagnostic demand boosts growth and margins expand, prompting higher 2026 revenue and earnings guidance.